v3.26.1
STOCKHOLDERS' DEFICIT (Tables)
3 Months Ended 12 Months Ended
Mar. 31, 2026
Dec. 31, 2025
STOCKHOLDERS' DEFICIT    
Summary of the Company's option activity

For the Three months ended

March 31, 2026

  ​ ​ ​

  ​ ​ ​

Weighted

  ​ ​ ​

 

average

Aggregate

Amount of

exercise

intrinsic

options *

price

value

$

$

Outstanding at December 31, 2025

 

51,656

34.19

 

Granted

 

 

Vested

 

(400)

25.95

 

Outstanding at March 31, 2026

 

51,256

34.25

 

Exercisable at March 31, 2026

 

43,934

34.36

 

*    Represents Employee Stock Options only (not including RSUs).

For the year ended December 31, 

2025

2024

Weighted

Weighted

Amount

average

Aggregate

Amount

average

Aggregate

Of

exercise

Intrinsic

Of

exercise

intrinsic

  ​ ​ ​

options(*)

  ​ ​ ​

price

  ​ ​ ​

Value

  ​ ​ ​

Options(*)

  ​ ​ ​

Price

  ​ ​ ​

value

$

$

$

$

Outstanding at beginning of period

86,359

34.55

107,052

49.01

Granted

Exercised

Forfeited

(34,703)

35.09

(20,693)

109.34

Outstanding at end of period

51,656

34.19

86,359

34.55

Vested at end of period

43,800

34.39

69,176

34.81

* Represents Employee Stock Options only (not including RSUs).

Schedule of restricted stock activity

  ​ ​ ​

  ​ ​ ​

  ​ ​ ​

Weighted Average

Remaining

Number of Shares

Weighted Average

Contractual

of Restricted

Grant Date Fair

Term

Stock

Value

(Years)

Nonvested as of December 31, 2025

 

310,854

3.01

 

0.45

Granted

 

 

Vested

 

57,605

4.95

 

Forfeited

 

 

Nonvested as of March 31, 2026

 

253,249

 

2.57

 

0.26

Weighted 

Average

Number of 

Weighted 

Remaining

Restricted

Average Grant

Contractual

  ​

Stock

  ​

Date Fair Value

  ​

Term (Years)

Nonvested as of December 31, 2023

 

20,327

(*) 42.90

 

1.32

Granted

 

115,210

(*) 4.95

 

Vested

 

6,679

(*) 38.73

 

Forfeited

 

7,572

(*)31.11

 

  ​

Nonvested as of December 31, 2024

 

121,286

6.69

0.72

Granted

 

688,666

2.14

 

Vested

 

469,098

2.74

 

Forfeited

 

30,000

2.14

 

  ​

Nonvested as of December 31, 2025

310,854

3.01

0.45

Schedule of total stock-based compensation expense

Three months ended

May 31,

  ​ ​ ​

2026

  ​ ​ ​

2025

Research and development

$

63

$

247

General and administrative

70

470

Total stock-based compensation expense

$

133

$

717

December 31, 

  ​ ​ ​

2025

  ​ ​ ​

2024

U.S. $ in thousands

Research and development

571

355

General and administrative

949

343

Total stock-based compensation expense

1,520

698